Found: 51
Select item for more details and to access through your institution.
Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 7, p. 1257, doi. 10.1002/ajh.27326
- By:
- Publication type:
- Article
Impact of academic medical center access on outcomes in multiple myeloma.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 1, p. 41, doi. 10.1002/ajh.26759
- By:
- Publication type:
- Article
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. 846, doi. 10.1002/ajh.26155
- By:
- Publication type:
- Article
Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 6, p. 690, doi. 10.1002/ajh.26166
- By:
- Publication type:
- Article
Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 3, p. 491, doi. 10.1111/ejh.14032
- By:
- Publication type:
- Article
Palliative care utilization, transfusion burden, and end‐of‐life care for patients with multiple myeloma.
- Published in:
- European Journal of Haematology, 2022, v. 109, n. 5, p. 559, doi. 10.1111/ejh.13843
- By:
- Publication type:
- Article
Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells.
- Published in:
- Molecules, 2021, v. 26, n. 15, p. 4658, doi. 10.3390/molecules26154658
- By:
- Publication type:
- Article
Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 11, p. e2342195, doi. 10.1001/jamanetworkopen.2023.42195
- By:
- Publication type:
- Article
Multiple Myeloma in Young Patients: A Scoping Review.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 1, p. 15, doi. 10.1016/j.clml.2023.08.019
- By:
- Publication type:
- Article
NS-66: Project to improve volume of treatment and satisfation-PIVOTS, a quality improvement project.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S168, doi. 10.1016/S2152-2650(21)02360-0
- By:
- Publication type:
- Article
P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S149, doi. 10.1016/S2152-2650(21)02329-6
- By:
- Publication type:
- Article
P-180: Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in newly diagnosed Multiple Myeloma (NDMM): analysis of vascular thrombotic events (VTEs) in the GRIFFIN study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S135, doi. 10.1016/S2152-2650(21)02307-7
- By:
- Publication type:
- Article
MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S419, doi. 10.1016/S2152-2650(21)01940-6
- By:
- Publication type:
- Article
Poster: MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥ 12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01576-7
- By:
- Publication type:
- Article
Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e353, doi. 10.1016/j.clml.2019.09.583
- By:
- Publication type:
- Article
Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e283, doi. 10.1016/j.clml.2019.09.466
- By:
- Publication type:
- Article
Targeted therapy in sarcomas other than GIST tumors.
- Published in:
- Journal of Surgical Oncology, 2015, v. 111, n. 5, p. 632, doi. 10.1002/jso.23802
- By:
- Publication type:
- Article
Long term responders in frontline multiple myeloma—exception vs expectation of the modern era.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01088-6
- By:
- Publication type:
- Article
Performance of newer myeloma staging systems in a contemporary, large patient cohort.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01076-w
- By:
- Publication type:
- Article
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01030-w
- By:
- Publication type:
- Article
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00993-0
- By:
- Publication type:
- Article
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00985-0
- By:
- Publication type:
- Article
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00886-8
- By:
- Publication type:
- Article
Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 12, p. 1, doi. 10.1038/s41408-022-00769-4
- By:
- Publication type:
- Article
Financial toxicity in hematological malignancies: a systematic review.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 4, p. 1, doi. 10.1038/s41408-022-00671-z
- By:
- Publication type:
- Article
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 5, p. 1, doi. 10.1038/s41408-021-00494-4
- By:
- Publication type:
- Article
How I manage patients with acquired haemophilia A.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 2, p. 157, doi. 10.1111/bjh.12228
- By:
- Publication type:
- Article
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker.
- Published in:
- BMC Cancer, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12885-021-08242-4
- By:
- Publication type:
- Article
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Hospitalization at the end of life in patients with multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
XRCC1‐mediated DNA repair is associated with progression‐free survival of multiple myeloma patients after autologous stem cell transplant.
- Published in:
- Molecular Carcinogenesis, 2019, v. 58, n. 12, p. 2327, doi. 10.1002/mc.23121
- By:
- Publication type:
- Article
Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant.
- Published in:
- Molecular Carcinogenesis, 2017, v. 56, n. 7, p. 1722, doi. 10.1002/mc.22626
- By:
- Publication type:
- Article
Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant.
- Published in:
- Cancer Genomics & Proteomics (1109-6535), 2023, v. 20, n. 1, p. 9, doi. 10.21873/cgp.20360
- By:
- Publication type:
- Article
Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 23, p. 3746, doi. 10.1002/cncr.34987
- By:
- Publication type:
- Article
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 22, p. 4198, doi. 10.1002/cncr.33809
- By:
- Publication type:
- Article
Sequence not salvage.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 5, p. 1590, doi. 10.1111/bjh.19439
- By:
- Publication type:
- Article
Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 5, p. 587, doi. 10.1111/bjh.18568
- By:
- Publication type:
- Article
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
- Published in:
- British Journal of Haematology, 2022, v. 199, n. 3, p. 355, doi. 10.1111/bjh.18432
- By:
- Publication type:
- Article
Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials.
- Published in:
- British Journal of Haematology, 2022, v. 197, n. 6, p. e86, doi. 10.1111/bjh.18102
- By:
- Publication type:
- Article
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 1, p. 74, doi. 10.1111/bjh.13527
- By:
- Publication type:
- Article
Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group.
- Published in:
- Frontiers in Health Services, 2024, p. 01, doi. 10.3389/frhs.2024.1354760
- By:
- Publication type:
- Article
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
- Published in:
- Ophthalmology & Therapy, 2020, v. 9, n. 4, p. 889, doi. 10.1007/s40123-020-00280-8
- By:
- Publication type:
- Article
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 599, doi. 10.1007/s00280-020-04229-3
- By:
- Publication type:
- Article
Pharmacokinetic‐Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High‐Dose Melphalan for Autologous Stem Cell Transplant.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2018, v. 7, n. 11, p. 748, doi. 10.1002/psp4.12345
- By:
- Publication type:
- Article
Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes.
- Published in:
- Human Molecular Genetics, 2021, v. 30, n. 12, p. 1142, doi. 10.1093/hmg/ddab066
- By:
- Publication type:
- Article
Toxicity management strategies for next-generation novel therapeutics in multiple myeloma.
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221100659
- By:
- Publication type:
- Article
Acquired Hemophilia A: A Current Review of Autoantibody Disease.
- Published in:
- Clinical Advances in Hematology & Oncology, 2012, v. 10, n. 1, p. 19
- By:
- Publication type:
- Article
Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma.
- Published in:
- 2022
- By:
- Publication type:
- letter